{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:05Z","timestamp":1790803685708,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200\u00a0mg\/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses &lt;\u20091200\u00a0mg\/day (low-dose group) and \u2265\u20091200\u00a0mg\/day (high-dose group). The adjusted mean changes in forced vital capacity (FVC) in 1\u00a0year were \u2212\u2009200.7, \u2212\u200988.4, and \u2212\u200994.7\u00a0mL in the control, low-dose, and high-dose groups (p\u2009=\u20090.021). The FVC declined more significantly in the control group than in the low-dose and high-dose groups. No significant difference in FVC change was observed between the low-dose and high-dose groups. Dyspepsia, anorexia, and nausea were significantly more frequent in the low-dose than in the high-dose group, suggesting that dose reduction is attributed to gastrointestinal tract-related adverse events. Dose reduction may help patients to better control gastrointestinal tract-related adverse events; continuing taking the medication at low doses is also expected to be effective in reducing the FVC decline.<\/jats:p>","DOI":"10.1038\/s41598-020-77837-x","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:06:08Z","timestamp":1607079968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital"],"prefix":"10.1038","volume":"10","author":[{"given":"Myung Jin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Woo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Soo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Soo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"77837_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"77837_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378, 1811\u20131823 (2018).","journal-title":"N. Engl. J. Med."},{"key":"77837_CR3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu, G. et al. An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788\u2013824 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"77837_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001\u20132011. Lancet Respir. Med. 2, 566\u2013572 (2014).","journal-title":"Lancet Respir. Med."},{"key":"77837_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","volume":"47","author":"PW Noble","year":"2016","unstructured":"Noble, P. W. et al. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. Eur. Respir. J. 47, 243\u2013253 (2016).","journal-title":"Eur. Respir. J."},{"key":"77837_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","volume":"196","author":"B Ley","year":"2017","unstructured":"Ley, B. et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196, 756\u2013761 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"77837_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","volume":"159","author":"G Raghu","year":"1999","unstructured":"Raghu, G., Johnson, W. C., Lockhart, D. & Mageto, Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159, 1061\u20131069 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"77837_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi, H. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 821\u2013829 (2010).","journal-title":"Eur. Respir. J."},{"key":"77837_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 377, 1760\u20131769 (2011).","journal-title":"Lancet"},{"key":"77837_CR10","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"77837_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/jcm5090078","volume":"5","author":"G Hughes","year":"2016","unstructured":"Hughes, G. et al. Real world experiences: Pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J. Clin. Med. 5, 78 (2016).","journal-title":"J. Clin. Med."},{"key":"77837_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/resp.13024","volume":"22","author":"JA Galli","year":"2017","unstructured":"Galli, J. A. et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology (Carlton, Vic.) 22, 1171\u20131178 (2017).","journal-title":"Respirology (Carlton, Vic.)"},{"key":"77837_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","volume":"53","author":"T Ogura","year":"2015","unstructured":"Ogura, T. et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir. Investig. 53, 232\u2013241 (2015).","journal-title":"Respir. Investig."},{"key":"77837_CR14","doi-asserted-by":"publisher","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","volume":"3","author":"L Lancaster","year":"2016","unstructured":"Lancaster, L. et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: Integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir. Res. 3, e000105 (2016).","journal-title":"BMJ Open Respir. Res."},{"key":"77837_CR15","first-page":"443","volume":"55","author":"TE King Jr","year":"2016","unstructured":"King, T. E. Jr. et al. Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Thorax 55, 443\u2013448 (2016).","journal-title":"Thorax"},{"key":"77837_CR16","doi-asserted-by":"publisher","first-page":"e000323","DOI":"10.1136\/bmjresp-2018-000323","volume":"5","author":"SD Nathan","year":"2018","unstructured":"Nathan, S. D. et al. Dose modification and dose intensity during treatment with pirfenidone: Analysis of pooled data from three multinational phase III trials. BMJ Open Respir. Res. 5, e000323 (2018).","journal-title":"BMJ Open Respir. Res."},{"key":"77837_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/resp.13145","volume":"23","author":"M Uehara","year":"2018","unstructured":"Uehara, M. et al. Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology (Carlton, Vic.) 23, 318\u2013324 (2018).","journal-title":"Respirology (Carlton, Vic.)"},{"key":"77837_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley, B. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 156, 684\u2013691 (2012).","journal-title":"Ann. Intern. Med."},{"key":"77837_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard, H. R. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 194, 265\u2013275 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"77837_CR20","doi-asserted-by":"publisher","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","volume":"26","author":"LH Lancaster","year":"2017","unstructured":"Lancaster, L. H. et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 26, 170057 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"77837_CR21","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois, D. & Du Bois, E. F. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (Burbank, Los Angeles County, Calif.) 5, 303\u2013311 (1989) (discussion 312\u2013303).","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77837-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:14:04Z","timestamp":1670372044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77837-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77837-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21218"}}